CY1117188T1 - Αντι-ιικο παραγωγο 1-φαινυλ-2,5-διβενζιμιδαζολ-5-υλ-πυρρολιδινης - Google Patents

Αντι-ιικο παραγωγο 1-φαινυλ-2,5-διβενζιμιδαζολ-5-υλ-πυρρολιδινης

Info

Publication number: CY1117188T1
Authority: CY; Cyprus
Prior art keywords: victive; divenzimidazol; fenyl; pyrrolidine; product
Prior art date: 2010-10-13

Application number

CY20161100115T

Other languages

Greek (el)

English (en)

Inventor

David A Degoey

Warren M Kati

Charles W Hutchins

Pamela L Donner

Allan C Krueger

John T Randolph

Christopher E Motter

Lissa T Nelson

Sachel V Patel

Mark A Matulenko

Ryan G Keddy

Tammie K Jinkerson

Yi Gao

Dachun Liu

John K Pratt

Todd W Rockway

Clarence J Maring

Douglas K Hutchinson

Charles A Flentge

Rolf Wagner

Michael D Tufano

David A Betebenner

Kathy Sarris

Kevin R Woller

Sebel H Wagaw

Jean C Califano

Wenke Li

Daniel D Caspi

Mary E Bellizzi

William A Carroll

Original Assignee

Abbvie Bahamas Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-13

Filing date

2016-02-12

Publication date

2017-04-05

2010-10-13 Priority claimed from US12/903,822 external-priority patent/US20110092415A1/en

2011-05-04 Priority claimed from US13/100,827 external-priority patent/US8937150B2/en

2016-02-12 Application filed by Abbvie Bahamas Ltd. filed Critical Abbvie Bahamas Ltd.

2017-04-05 Publication of CY1117188T1 publication Critical patent/CY1117188T1/el

Links

RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
241000711549 Hepacivirus C Species 0.000 abstract 3
208000015181 infectious disease Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000010076 replication Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CY20161100115T 2010-10-13 2016-02-12 Αντι-ιικο παραγωγο 1-φαινυλ-2,5-διβενζιμιδαζολ-5-υλ-πυρρολιδινης CY1117188T1 (el)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US12/903,822 US20110092415A1 (en)	2009-06-11	2010-10-13	Anti-Viral Compounds
US12/964,027 US8921514B2 (en)	2009-06-11	2010-12-09	Anti-viral compounds
US201161446800P	2011-02-25	2011-02-25
US13/100,827 US8937150B2 (en)	2009-06-11	2011-05-04	Anti-viral compounds
EP13191041.6A EP2692346B1 (en)	2010-10-13	2011-10-12	An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative

Publications (1)

Publication Number	Publication Date
CY1117188T1 true CY1117188T1 (el)	2017-04-05

Family

ID=55069204

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY20161100115T CY1117188T1 (el)	2010-10-13	2016-02-12	Αντι-ιικο παραγωγο 1-φαινυλ-2,5-διβενζιμιδαζολ-5-υλ-πυρρολιδινης

Country Status (19)

Country	Link
JP (4)	JP2016106075A (zh)
KR (1)	KR101990936B1 (zh)
CA (1)	CA2938547A1 (zh)
CY (1)	CY1117188T1 (zh)
DK (1)	DK2692346T3 (zh)
ES (1)	ES2560842T3 (zh)
GT (1)	GT201300093AA (zh)
HK (1)	HK1188717A1 (zh)
HR (1)	HRP20151389T1 (zh)
HU (1)	HUE026832T2 (zh)
IL (2)	IL225010A (zh)
ME (1)	ME02328B (zh)
MY (1)	MY164064A (zh)
PT (1)	PT2692346E (zh)
RS (1)	RS54619B1 (zh)
SI (1)	SI2692346T1 (zh)
TW (1)	TWI621611B (zh)
UA (1)	UA113048C2 (zh)
ZA (3)	ZA201302269B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201706806D0 (en) *	2017-04-28	2017-06-14	Sentinel Oncology Ltd	Pharmaceutical compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU221816B1 (hu) *	1991-10-11	2003-01-28	Bristol-Myers Squibb Pharma Company	Gyűrűs karbonil vegyületek, és ezeket tartalmazó gyógyászati készítmények
US5840721A (en) *	1997-07-09	1998-11-24	Ontogen Corporation	Imidazole derivatives as MDR modulators
US8329159B2 (en) *	2006-08-11	2012-12-11	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7741347B2 (en) *	2007-05-17	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2373168A4 (en) *	2008-12-03	2012-08-01	Presidio Pharmaceuticals Inc	HCV NS5A SHEMMER
US8937150B2 (en) *	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
UY32699A (es) *	2009-06-11	2010-12-31	Abbott Lab	Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados
US9394279B2 (en) *	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds

2011
- 2011-10-12 ES ES13191041.6T patent/ES2560842T3/es active Active
- 2011-10-12 MY MYPI2013700273A patent/MY164064A/en unknown
- 2011-10-12 CA CA2938547A patent/CA2938547A1/en not_active Abandoned
- 2011-10-12 TW TW102143104A patent/TWI621611B/zh active
- 2011-10-12 RS RS20160128A patent/RS54619B1/en unknown
- 2011-10-12 DK DK13191041.6T patent/DK2692346T3/en active
- 2011-10-12 HU HUE13191041A patent/HUE026832T2/en unknown
- 2011-10-12 KR KR1020187004491A patent/KR101990936B1/ko active IP Right Grant
- 2011-10-12 PT PT131910416T patent/PT2692346E/pt unknown
- 2011-10-12 ME MEP-2016-14A patent/ME02328B/me unknown
- 2011-10-12 SI SI201130697T patent/SI2692346T1/sl unknown
- 2011-12-10 UA UAA201305877A patent/UA113048C2/uk unknown
2013
- 2013-02-28 IL IL225010A patent/IL225010A/en active IP Right Grant
- 2013-03-26 ZA ZA2013/02269A patent/ZA201302269B/en unknown
2014
- 2014-01-13 GT GT201300093AK patent/GT201300093AA/es unknown
- 2014-02-25 HK HK14101772.6A patent/HK1188717A1/zh unknown
2015
- 2015-10-29 JP JP2015212539A patent/JP2016106075A/ja active Pending
- 2015-12-17 HR HRP20151389TT patent/HRP20151389T1/hr unknown
2016
- 2016-02-12 CY CY20161100115T patent/CY1117188T1/el unknown
2017
- 2017-08-15 ZA ZA2017/05519A patent/ZA201705519B/en unknown
- 2017-11-22 JP JP2017224527A patent/JP6586147B2/ja active Active
2018
- 2018-08-16 IL IL261206A patent/IL261206B/en active IP Right Grant
2019
- 2019-05-24 ZA ZA2019/03284A patent/ZA201903284B/en unknown
- 2019-09-05 JP JP2019161909A patent/JP6790202B2/ja active Active
2020
- 2020-11-02 JP JP2020183474A patent/JP2021035964A/ja active Pending

Also Published As

Publication number	Publication date
JP6790202B2 (ja)	2020-11-25
ME02328B (me)	2016-06-20
IL261206B (en)	2019-12-31
SI2692346T1 (sl)	2016-03-31
IL261206A (en)	2018-10-31
IL225010A (en)	2016-04-21
JP2016106075A (ja)	2016-06-16
DK2692346T3 (en)	2016-02-29
GT201300093AA (es)	2015-07-08
HK1188717A1 (zh)	2014-05-16
JP2021035964A (ja)	2021-03-04
ES2560842T3 (es)	2016-02-23
HUE026832T2 (en)	2016-07-28
ZA201903284B (en)	2021-01-27
TWI621611B (zh)	2018-04-21
ZA201705519B (en)	2019-04-24
MY164064A (en)	2017-11-15
JP2020059696A (ja)	2020-04-16
JP2018065828A (ja)	2018-04-26
RS54619B1 (en)	2016-08-31
KR101990936B1 (ko)	2019-06-19
KR20180026775A (ko)	2018-03-13
TW201412707A (zh)	2014-04-01
HRP20151389T1 (hr)	2016-01-15
CA2938547A1 (en)	2012-04-19
ZA201302269B (en)	2021-05-26
JP6586147B2 (ja)	2019-10-02
UA113048C2 (xx)	2016-12-12
PT2692346E (pt)	2016-03-22

Publication	Publication Date	Title
CY1114356T1 (el)	2016-04-13	Αναστολεις του ιου της ηπατιτιδας c
EA201390190A1 (ru)	2013-06-28	Ингибиторы вируса гепатита с
MX2020002151A (es)	2020-07-13	Compuestos antivirales.
EA201101082A1 (ru)	2012-02-28	Ингибиторы вируса гепатита с
EA201171208A1 (ru)	2012-05-30	Ингибиторы вируса гепатита с
EA201391152A1 (ru)	2013-12-30	Ингибиторы вируса гепатита с
EA201270622A1 (ru)	2012-12-28	Ингибиторы вируса гепатита с
MX346264B (es)	2017-03-13	Compuestos antivirales.
EA201270656A1 (ru)	2012-11-30	Ингибиторы вируса гепатита с
EA201370017A1 (ru)	2013-05-30	Ингибиторы вируса гепатита с
CY1118567T1 (el)	2017-07-12	Αναστολεις του ιου της ηπατιτιδας c
EA201001275A1 (ru)	2011-06-30	Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
CO6390076A2 (es)	2012-02-29	Inhibidores de hcv ns5a
CO6390077A2 (es)	2012-02-29	Inhibidores de hacv ns5a
EA201691261A1 (ru)	2016-11-30	Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201691726A1 (ru)	2016-12-30	Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201270555A1 (ru)	2012-09-28	Комбинации ингибиторов вируса гепатита с
EA201001273A1 (ru)	2011-08-30	Ингибиторы вируса гепатита с
CY1122442T1 (el)	2021-01-27	Μεθοδοι για την αγωγη ηπατιτιδας c
EA201390155A1 (ru)	2013-05-30	Комбинации ингибиторов вируса гепатита с
EA201791776A1 (ru)	2018-04-30	Замещенные циклофаны для использования при лечении инфекции вгс
MX2011010905A (es)	2011-11-01	Compuestos antivirales.
EA201490654A1 (ru)	2014-11-28	Новые ингибиторы вирусной репликации
UY32721A (es)	2011-01-31	Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
EA201391685A1 (ru)	2014-03-31	Ингибиторы вируса гепатита с